Prelude Therapeutics Inc
1 day chart
Prelude Therapeutics Inc. is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. The Company’s product candidate pipeline includes PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT3645. PRT543 is in a Phase I clinical trial in advanced solid tumors and select myeloid malignancies. PRT811 is a being studied in a Phase I clinical trial in unselected patients with solid tumors, including high-grade glioma. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is designed to be a potent and selective Cyclin-dependent kinase 9 (CDK9), inhibitor. The Company’s drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders.
Buy US stocks in Australia with $0 brokerage and trade PRLD today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.